TMToru Miyajima

Toru Miyajima

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Toru Miyajima has a total of 94 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Early administration of calcineurin inhibitors limits the tolerogenic effect of PTCy in allogeneic hematopoietic transplant

    by Keisuke Kojima, Hajime Senjo, Shihori Tsukamoto, Ayumu Ito, Shimpei I. Kubota, Kaoru Murakami, Asako Moriki, Tomoe Ichiki, Toru Miyajima, Yumika Saito, et al.

    We recently demonstrated that early administration of calcineurin inhibitors (CNIs) after murine allogeneic hematopoietic cell transplantation (allo-HCT) inhibits terminal exhaustion of donor T cells and hampers tolerance induction. However, the role of CNIs in regulating T-cell exhaustion in clinical allo-HCT remains to be clarified. It also remains to be elucidated why posttransplant cyclophosphamide (PTCy) can reduce chronic graft-versus-host disease (cGVHD), despite the administration of CNIs. In this study, we explored the impact of CNIs on donor T-cell exhaustion after PTCy-based haploidentical HCT. In mice, early administration of cyclosporine before PTCy preserved a population of Ly6C+ donor T cells with less exhausted characteristics, as has been shown in non-PTCy allo-HCT. In single-cell analyses of clinical samples from patients undergoing HLA-haploidentical peripheral blood stem cell transplantation with PTCy (PTCy-haplo-PBSCT), early administration of tacrolimus before PTCy promoted the expansion of effector-like CD8+ intermediate-exhausted T cells (Tex-int) and CD4+ cytotoxic T cells (CTLs), with the former enriched for both effector- and exhaustion-associated gene signatures, whereas the latter for effector- and CD4+ CTL–specific gene signatures. These subsets retained high responsiveness to T-cell receptor stimulation and PD-1 blockade, and their expansion on day 28 predicted subsequent cGVHD. In contrast, delaying tacrolimus administration until day 5 after PTCy-haplo-PBSCT significantly reduced the expansion of these effector-like T cells. These findings indicate that early CNI exposure favors the persistence of incompletely exhausted and clonally expanded donor T cells with pathogenic potential. Tex-int and CD4+ CTLs may serve as prognostic biomarkers of cGVHD risk and as promising targets for preemptive therapy for cGVHD.


  • Successful treatment with zanubrutinib for Bing-Neel syndrome progressing on ibrutinib: a case report and literature review

    by Shingo Nojima, Toru Miyajima, Reiki Ogasawara, Shota Yoshida, Hiroyuki Kimura, Rintaro Nozu, Fuka Horikita, Takahide Ara, Toshihiro Matsukawa, Souichi Shiratori, et al.

  • Open Access

    Adenovirus‐Associated Opsoclonus After Allogeneic Hematopoietic Stem Cell Transplantation

    by Toru Miyajima, Setsuaki Hoshino, Shingo Nojima, Souichi Shiratori, Taishi Iwanami, Takanori Teshima

  • GVHD targets organoid-forming bile duct stem cells in a TGF-β–dependent manner

    by Yuta Hasegawa, Daigo Hashimoto, Zixuan Zhang, Toru Miyajima, Yumika Saito, Wenyu Li, Ryo Kikuchi, Hajime Senjo, Tomoko Sekiguchi, Takahiro Tateno, et al.

    Graft-versus-host disease (GVHD) is a major life-threatening complication that occurs after allogeneic hematopoietic cell transplantation (HCT). Although adult tissue stem cells have been identified as targets of GVHD in the skin and gut, their role in hepatic GVHD is yet to be clarified. In the current study, we explored the fate of bile duct stem cells (BDSCs), capable of generating liver organoids in vitro, during hepatic GVHD after allogeneic HCT. We observed a significant expansion of biliary epithelial cells (BECs) on injury early after allogeneic HCT. Organoid-forming efficiency from the bile duct was also significantly increased early after allogeneic HCT. Subsequently, the organoid-forming efficiency from bile ducts was markedly decreased in association with the reduction of BECs and the elevation of plasma concentrations of bilirubin, suggesting that GVHD targets BDSCs and impairs the resilience of BECs. The growth of liver organoids in the presence of liver-infiltrating mononuclear cells from allogeneic recipients, but not from syngeneic recipients, was significantly reduced in a transforming growth factor-β (TGF-β)–dependent manner. Administration of SB-431542, an inhibitor of TGF-β signaling, from day 14 to day 28, protected organoid-forming BDSCs against GVHD and mitigated biliary dysfunction after allogeneic HCT, suggesting that BDSCs are a promising therapeutic target for hepatic GVHD.


  • Clinical implications of NUP98::NSD1 fusion at diagnosis in adult FLT3‐ITD positive AML

    by Toru Miyajima, Masahiro Onozawa, Shota Yoshida, Naoki Miyashita, Hiroyuki Kimura, Shogo Takahashi, Shota Yokoyama, Toshihiro Matsukawa, Hideki Goto, Junichi Sugita, et al.

    Objectives: The cryptic fusion oncogene NUP98::NSD1 is known to be associated with FLT3‐ITD mutation in acute myeloid leukemia (AML), and an independent poor prognostic factor in pediatric AML. However, there are little data regarding the clinical significance of NUP98::NSD1 in adult cohort.Methods: We conducted a multicenter retrospective study to investigate the prevalence, clinical characteristics, and prognostic impact of NUP98::NSD1 in adult FLT3‐ITD‐positive AML patients.Results: In a total of 97 FLT3‐ITD‐positive AML patients, six cases (6.2%) were found to harbor the NUP98::NSD1 fusion transcript. NUP98::NSD1 positive cases had significantly higher platelet counts and a higher frequency of FAB‐M4 morphology than NUP98::NSD1 negative cases. NUP98::NSD1 was found to be mutually exclusive with NPM1 mutation, and was accompanied by the WT1 mutation in three of the six cases. The presence of NUP98::NSD1 fusion at the time of diagnosis predicted poor response to cytarabine‐anthracycline‐based intensive induction chemotherapy (induction failure rate: 83% vs. 36%, p = .038). Five of the six cases with NUP98::NSD1 underwent allogeneic hematopoietic stem cell transplantation (HSCT). Two of the five cases have successfully maintained remission, with one of them being rescued through a second HSCT.Conclusions: Detecting NUP98::NSD1 in adult FLT3‐ITD‐positive AML is crucial to recognizing chemotherapy‐resistant group.


  • Open Access

    Neurolymphomatosis in Intravascular Large B-cell Lymphoma

    by Toru Miyajima, Hiroyuki Ohigashi, Hiroaki Yaguchi, Takanori Teshima

    Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.


  • Thiotepa-based high-dose chemotherapy with autologous stem cell transplantation for neurolymphomatosis

    by Toru Miyajima, Reiki Ogasawara, Shihori Tsukamoto, Takashi Ishio, Emi Yokoyama, Koh Izumiyama, Akio Mori, Makoto Saito, Masanobu Morioka, Takeshi Kondo

    Neurolymphomatosis (NL) is a rare clinical entity characterized by lymphomatous infiltration of the peripheral nervous system. According to recent retrospective data, consolidative high-dose chemotherapy (HDC) with autologous stem cell transplantation (ASCT) may be beneficial for NL. However, few reports to date have discussed optimal conditioning regimens. Herein, we report two cases of NL in patients with relapsed intravascular large B-cell lymphoma who received consolidative thiotepa-containing HDC-ASCT. Case 1: A 56-year-old woman who relapsed 2 months after the first complete remission (CR) and underwent ASCT. Case 2: A 65-year-old woman who relapsed 8 months after the first CR and underwent ASCT. Both patients engrafted. Time to neutrophil engraftment was 10 and 12 days after HDC-ASCT, and CR was sustained for 26 and 18 months, respectively, as of the last follow-up. Although there is little evidence supporting the utility of thiotepa-based HDC-ASCT in patients with NL, the results of this case report suggest that further studies are warranted to determine its efficacy in this setting.


  • [Successful treatment with gilteritinib for relapsed acute myeloid leukemia with FLT3-N676K mutation].

    by Toru Miyajima, Shinpei Harada, Reiki Ogasawara, Emi Yokoyama, Koh Izumiyama, Akio Mori, Makoto Saito, Masanobu Morioka, SungGi Chi, Yosuke Minami, et al.

    The patient was a 68-year-old woman, diagnosed with acute myelomonocytic leukemia with normal karyotype and FLT3-ITD-negative status in May 2019. She had achieved complete remission (CR) after "7+3" intensive induction chemotherapy and maintained CR by consolidation chemotherapy. However, she relapsed with swelling of the lips and gums in January 2020. She did not achieve CR by salvage chemotherapy with cytarabine-aclarubicin-G-CSF regimen. Comprehensive genomic analysis of leukemic cells revealed the presence of FLT3-N676K mutation, which was undetectable by companion diagnostics at the time. Complete remission with incomplete count recovery was obtained on day 28 after initiation of gilteritinib monotherapy, and the lip and gum swelling improved rapidly. However, she relapsed on day 106 after gilteritinib administration, and gilteritinib was discontinued. Genomic analysis at recurrence revealed NRAS mutation for the first time. Finally, the patient died of the uncontrolled primary disease. This is a case in which comprehensive gene mutation analysis was useful in determining a treatment strategy.


  • Non-age-related neoplastic loss of sex chromosome correlated with prolonged survival in real-world CBF-AML patients

    by Akio Mori, Masahiro Onozawa, Daisuke Hidaka, Shota Yokoyama, Toru Miyajima, Emi Yokoyama, Reiki Ogasawara, Koh Izumiyama, Makoto Saito, Shinichi Fujisawa, et al.

    In this real-world clinical study, in which we determined eligibility for allogenic hematopoietic stem cell transplantation by prognostic factors and minimal residual disease status, we retrospectively evaluated cytogenetic, genetic, and clinical features in 96 patients with core-binding factor acute myeloid leukemia (CBF-AML) including 62 patients with RUNX1/RUNX1T1 and 34 patients with CBFβ/MYH11. Multivariate analyses for 5-year overall survival (OS) in CBF-AML patients revealed that age of 50 years or older (HR: 3.46, 95% CI 1.47–8.11, P = 0.004) and receiving 2 or more induction cycles (HR: 3.55, 95% CI 1.57–8.05, P = 0.002) were independently associated with worse OS and that loss of sex chromosome (LOS) was independently associated with better OS (HR: 0.09, 95% CI 0.01–0.71, P = 0.022). At the time of complete remission, all 21 karyotyped patients with LOS had a normal karyotype. Furthermore, in all 9 patients with LOS who had a mosaic of metaphase cells with and without t(8;21) or inv(16), the metaphase cells without t(8;21)/inv(16) showed a normal karyotype. These results proved that LOS was not age-related and physiological, but rather a neoplastic chromosomal abnormality.